Clin Endosc.  2011 Dec;44(2):101-108. 10.5946/ce.2011.44.2.101.

Low Grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Clinicopathological Factors Associated with Helicobacter pylori Eradication and Tumor Regression

• Choi YJ
• Lee DH
• Kim JY
• Kwon JE
• Kim JY
• Jo HJ
• Shin CM
• Kim HY
• Park YS
• Kim N
• Jung HC
• Song IS

• KMID: 1805256
• DOI: http://doi.org/10.5946/ce.2011.44.2.101

Abstract

BACKGROUND/AIMS
Eradication of Helicobacter pylori is widely accepted as initial therapy for low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, approximately 20% of patients with this disease are not responsive to H. pylori eradication therapy. The aim of this study was to assess remission and relapse rates of low-grade gastric MALT lymphoma after H. pylori eradication and identify the clinical factors that affect remission.
METHODS
Thirty-nine patients diagnosed with gastric MALT lymphoma (May 2003 to May 2010) were retrospectively analyzed.
RESULTS
Of the 39 patients, 30 (77%) had a H. pylori infection. There were 35/39 (90%) patients with stage I. Among stage I, 25 patients with the infection underwent eradication therapy and 22/25 (88%) achieved remission. The total regression rate with eradication only in stage I was 24/28 (86%). The median time to remission was 98 days (range, 22 to 397 days). Age, tumor location, invasion depth, H. pylori burden, and severity of mononuclear leukocyte and neutrophil infiltration were not related to remission. However, patients with less neutrophil infiltration were more likely to achieve a successful first H. pylori eradication (p=0.049).
CONCLUSIONS
The results show that the rate of low-grade gastric MALT lymphoma regression (86%) with H. pylori eradication alone was higher than that in Western studies (77.8%) and that neutrophil infiltration was inversely related to success of the first H. pylori eradication procedure.

Keyword

Mucosa-associated lymphoid tissue; Lymphoma; Helicobacter pylori; Eradication; Remission

MeSH Terms

Helicobacter
Helicobacter pylori
Humans
Leukocytes, Mononuclear
Lymphoid Tissue
Lymphoma
Lymphoma, B-Cell, Marginal Zone
Neutrophil Infiltration
Recurrence
Retrospective Studies

Figure

• 

  Fig. 1 Therapeutic scheme of 39 mucosa-associated lymphoid tissue (MALT) lymphoma cases at a uni-center study of Seoul National University Bundang Hospital cases from May 2003 to May 2010. Among 39 patients, 26 patients took eradication therapies. CR, complete remission; PR, partial remission; CT, chemotherapy; RT, radiotherapy; FU, follow-up. a)Include 2nd-line eradication therapy.

• 

  Fig. 2 Trend between the neutrophil infiltration and the eradication. The less neutrophil infiltration tends to have the higher chance of success in the first eradication. G1, group which achieved first eradication success; G2, group which obtained eradication after the second eradication.

• 

  Fig. 3 Occurrence of complete remission (CR) event. Kaplan-Meier distribution shows the half of remission occurred within 111 days.

Reference

1. Brooks JJ, Enterline HT. Primary gastric lymphomas. A clinicopathologic study of 58 cases with long-term follow-up and literature review. Cancer. 1983; 51:701–711. PMID: 6336982.

2. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972; 29:252–260. PMID: 5007387.

3. Lim FE, Hartman AS, Tan EG, Cady B, Meissner WA. Factors in the prognosis of gastric lymphoma. Cancer. 1977; 39:1715–1720. PMID: 322839.

4. Sandler RS. Has primary gastric lymphoma become more common? J Clin Gastroenterol. 1984; 6:101–107. PMID: 6715847.

5. Severson RK, Davis S. Increasing incidence of primary gastric lymphoma. Cancer. 1990; 66:1283–1287. PMID: 2400976.

6. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983; 52:1410–1416. PMID: 6193858.

7. Enno A, O'Rourke JL, Howlett CR, Jack A, Dixon MF, Lee A. MALToma-like lesions in the murine gastric mucosa after long-term infection with Helicobacter felis. A mouse model of Helicobacter pylori-induced gastric lymphoma. Am J Pathol. 1995; 147:217–222. PMID: 7604881.

8. Isaacson PG, Spencer J. Gastric lymphoma and Helicobacter pylori. Important Adv Oncol. 1996; 111–121. PMID: 8791131.

9. Nakamura S, Aoyagi K, Furuse M, et al. B-cell monoclonality precedes the development of gastric MALT lymphoma in Helicobacter pylori-associated chronic gastritis. Am J Pathol. 1998; 152:1271–1279. PMID: 9588895.

10. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994; 330:1267–1271. PMID: 8145781.

11. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991; 338:1175–1176. PMID: 1682595.

12. Pinotti G, Zucca E, Roggero E, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma. 1997; 26:527–537. PMID: 9389360.

13. Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW. Textbook of Gastroenterology. 2008. 5th ed. Oxford: Wiley-Blackwell;p. 1044–1046.

14. Eck M, Schmausser B, Haas R, Greiner A, Czub S, Müller-Hermelink HK. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology. 1997; 112:1482–1486. PMID: 9136825.

15. Wotherspoon AC. Gastric lymphoma of mucosa-associated lymphoid tissue and Helicobacter pylori. Annu Rev Med. 1998; 49:289–299. PMID: 9509264.

16. Zullo A, Hassan C, Andriani A, et al. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol. 2009; 104:1932–1937. PMID: 19532131.

17. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004; 53:34–37. PMID: 14684573.

18. Suzuki H, Saito Y, Hibi T. Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) lymphoma: updated review of clinical outcomes and the molecular pathogenesis. Gut Liver. 2009; 3:81–87. PMID: 20431728.

19. Wündisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005; 23:8018–8024. PMID: 16204012.

20. Lee SK, Lee YC, Chung JB, et al. Endoscopic findings and results of long-term follow-up of low grade gastric MALT lymphoma. Korean J Gastrointest Endosc. 2003; 26:192–198.

21. Park KJ, Kim DH, Kim SH, et al. A clinical study of the therapeutic outcome of low-grade gastric MALT lymphoma. Chonnam Med J. 2006; 42:94–100.

22. Hong SS, Jung HY, Choi KD, et al. A prospective analysis of low-grade gastric malt lymphoma after Helicobacter pylori eradication. Helicobacter. 2006; 11:569–573. PMID: 17083379.

23. Fischbach W, Dragosics B, Kolve-Goebeler ME, et al. The German-Austrian Gastrointestinal Lymphoma Study Group. Primary gastric B-cell lymphoma: results of a prospective multicenter study. Gastroenterology. 2000; 119:1191–1202. PMID: 11054376.

24. Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999; 131:88–95. PMID: 10419446.

25. Stolte M, Bayerdörffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut. 2002; 50(Suppl 3):III19–III24. PMID: 11953328.

26. Chung JB. Gastroenterology. 2009. 1st ed. Seoul: Koonja;p. 322–323.

27. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001; 357:39–40. PMID: 11197361.

28. Nakamura T, Inagaki H, Seto M, Nakamura S. Gastric low-grade B-cell MALT lymphoma: treatment, response, and genetic alteration. J Gastroenterol. 2003; 38:921–929. PMID: 14614598.

29. Sleisenger MH, Fordtran JS, Feldman ML, Scharschmidt B. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 1998. 6th ed. Philadelphia: Saunders;p. 450–452.

30. Kim SJ, Yang S, Min BH, et al. Helicobacter pylori eradication for stage IE1 gastric mucosa-associated lymphoid tissue lymphoma: predictive factors of complete remission. Korean J Gastroenterol. 2010; 55:94–99. PMID: 20168055.

31. Gisbert JP, Olivares D, Jimenez I, Pajares JM. Long-term follow-up of 13C-urea breath test results after Helicobacter pylori eradication: frequency and significance of borderline delta13CO2 values. Aliment Pharmacol Ther. 2006; 23:275–280. PMID: 16393307.